Merck & Co bolsters hepatitis C pipeline with Idenix acquisition


US drug firm Merck & Co has agreed to buy hepatitis C specialist Idenix for $3.85 billion (£2.3 billion). The deal gives Merck access to three investigational drug candidates from Idenix’s pipeline, which it hopes will complement treatments being developed in-house.

The most advanced of Idenix’s compounds, samatasvir, inhibits the virus’ non-structural protein 5A, which is involved in replicating viral RNA. It is currently in Phase II clinical trials. The other two, IDX21437 and IDX21459, are nucleotide prodrugs based on uridine, designed to inhibit RNA replication. Both are in Phase I trials.

The high price Merck is willing to pay for these early-stage assets (more than triple the value of Idenix’s shares before the announcement) indicates the company’s confidence in the longevity of the hepatitis C market. It also shows Merck’s desire to compete with the likes of Gilead’s Sovaldi (sofosbuvir), which has made over $2 billion in sales in the first quarter of this year since its approval in December 2013, despite complaints about its high price. The possibility of an all-oral treatment that is effective across the full range of viral genotypes, as well as eliminating the side effects caused by combining drugs with interferon and/or ribavirin is a tantalising goal, but as more drugs are introduced, competition will eat away at the price premium each can charge.


Related Content

Bayer wins race to buy Merck & Co consumer care

9 May 2014 Business

news image

$14bn deal will make Aspirin inventor the number two over-the-counter healthcare company

AstraZeneca stocks pipeline with acquisitions

10 June 2013 Business

news image

Spending spree continues with two more deals

Most Read

Antimicrobial resistance will kill 300 million by 2050 without action

16 December 2014 News and Analysis

news image

UK report says resistance will cost global economy $100 trillion

Cutting edge chemistry in 2014

10 December 2014 Research

news image

We take a look back at the year's most interesting chemical science stories

Most Commented

A bad business

19 December 2014 Critical Point

news image

Targets and assessments can boost productivity at universities – but only if they do not stifle creativity and alienate the...

Chemistry behind the ‘blue man’ unlocked

1 November 2012 Research

news image

Biochemical model suggests that silver ions, not nanoparticles, cause a rare skin complaint